|
The diabetes drug Rezulin was withdrawn from the
market on Tuesday following a request from the US Food and Drug Administration
(FDA). The drug, which lowers blood sugar in diabetics, has been linked
to potentially life-threatening liver failure in some patients. Rezulin
had generated revenues of $625 million in 1997 and $748 million in 1998,
but Warner-Lambert expected sales to fall to $400 million this year due
to safety concerns. There are currently about 500,000 patients taking
Rezulin.
| 